Cardinal Health Reports 19% Revenue Growth in Q2 FY26
Written by Emily J. Thompson, Senior Investment Analyst
Updated: Feb 05 2026
0mins
Should l Buy CAH?
Source: PRnewswire
- Significant Revenue Growth: Cardinal Health reported revenues of $65.6 billion for Q2 FY26, marking a 19% increase from Q2 FY25, indicating strong performance across all business segments, particularly in Pharmaceutical and Specialty Solutions.
- Improved Profitability: GAAP operating earnings rose 29% to $707 million, while non-GAAP operating earnings increased by 38% to $877 million, reflecting effective strategies in cost control and market demand, thereby enhancing overall profitability.
- Earnings Per Share Growth: GAAP diluted EPS grew by 19% to $1.97, and non-GAAP diluted EPS surged by 36% to $2.63, showcasing the company's success in reducing share count and improving earnings, which further boosts investor confidence.
- Upgraded Fiscal Outlook: Cardinal Health raised its fiscal year 2026 guidance for non-GAAP diluted EPS to a range of $10.15 to $10.35, projecting growth of 23% to 26%, reflecting the company's optimistic outlook for future performance and sustained market competitiveness.
Trade with 70% Backtested Accuracy
Stop guessing "Should I Buy CAH?" and start using high-conviction signals backed by rigorous historical data.
Sign up today to access powerful investing tools and make smarter, data-driven decisions.
Analyst Views on CAH
Wall Street analysts forecast CAH stock price to rise
11 Analyst Rating
10 Buy
1 Hold
0 Sell
Strong Buy
Current: 212.020
Low
209.00
Averages
225.18
High
244.00
Current: 212.020
Low
209.00
Averages
225.18
High
244.00
About CAH
Cardinal Health, Inc. is a global healthcare services and products company. The Company is engaged in providing customized solutions for hospitals, healthcare systems, pharmacies, ambulatory surgery centers, clinical laboratories, physician offices and patients in the home. The Company also provides pharmaceuticals and medical products. Its segments include Pharmaceutical and Specialty Solutions and Global Medical Products and Distribution (GMPD). The Pharmaceutical and Specialty Solutions segment distributes branded and generic pharmaceuticals, specialty pharmaceuticals and over-the-counter healthcare and consumer products in the United States, as well as it owns urology MSO. Its GMPD segment manufactures, sources and distributes Cardinal Health branded medical, surgical and laboratory products, which are sold in the United States, Canada, Europe, Asia and other markets. The Company connects patients, providers, payers, pharmacists and manufacturers for integrated care coordination.
About the author
Emily J. Thompson
Emily J. Thompson, a Chartered Financial Analyst (CFA) with 12 years in investment research, graduated with honors from the Wharton School. Specializing in industrial and technology stocks, she provides in-depth analysis for Intellectia’s earnings and market brief reports.
Cardinal Health Expands Ac-225 Production Capacity Significantly
- Production Capacity Boost: Cardinal Health has added a high-capacity production line at its Center for Theranostics Advancement in Indianapolis, significantly increasing the supply of cGMP-compliant Ac-225 to meet the growing demand for cancer therapies.
- Clinical Trial Support: To date, Cardinal Health's Ac-225 has supported over 15 clinical trials worldwide, reflecting the company's extensive engagement in advancing targeted alpha therapies and enhancing its position in pharmaceutical innovation.
- Market Demand Response: Since announcing routine global production at scale at the end of 2024, Cardinal Health has quadrupled its weekly output, with expectations to continue increasing production capacity in 2026 to meet the rapidly growing demand for targeted alpha therapies.
- Supply Chain Assurance: According to VP Shane Thrasher, expanding Ac-225 production capacity is a critical advancement for the industry and patients, ensuring reliable access to targeted alpha therapies and preparing for larger commercial volumes in the future.
See More
Market Volatility and Amazon's Acquisition Talks
- Market Volatility: Stocks experienced significant declines at the open on Thursday due to President Trump's hawkish remarks on the Iran war, which raised concerns and caused oil prices to surge; however, news of Iran working with Oman on a shipping protocol eased oil price pressures, allowing the S&P 500 to briefly trade higher, reflecting the market's high uncertainty.
- Amazon Acquisition Talks: Amazon is in negotiations to acquire satellite company Globalstar to advance its internet-from-space service, Leo, having launched about 200 low Earth orbit satellites despite competition from SpaceX's Starlink, which has over 10,000 satellites; this move is expected to enhance rural internet access and make Prime membership more attractive.
- Microsoft's AI Investment Lag: A profile on Microsoft CFO Amy Mood highlighted the company's conservative approach to AI spending, which has led to a competitive disadvantage, with the stock down 23% year-to-date; nevertheless, analysts remain optimistic about management's ability to address these challenges, maintaining a $600 price target.
- Rapid Stock Review: Stocks mentioned in Thursday's rapid-fire segment included Brinker, Texas Roadhouse, and Constellation Brands, indicating a focus on diversified investment strategies while emphasizing Jim Cramer's long-term holding approach in specific stocks within his charitable trust.
See More
CNBC Investing Club March Meeting Overview
- Energy Stocks Surge: Following the outbreak of war in Iran, energy stocks, particularly fertilizer manufacturers, have shown strong performance, indicating robust market demand that could drive profitability for related companies.
- AWS Growth Acceleration: Amazon's cloud unit AWS is no longer lagging behind Microsoft Azure, thanks to its partnership with Anthropic, with expectations for next quarter's margins to exceed market forecasts, boosting investor confidence.
- Cybersecurity Challenges: CrowdStrike has been affected by turmoil in the software market, but the CEO highlighted the positive impact of AI on cyberattacks, indicating long-term growth potential in the security sector, despite high stock prices.
- Healthcare Sector Risks: Eli Lilly faces pricing pressure from competitor Novo Nordisk, but the company is prepared to counter this by increasing volume, with the upcoming launch of its GLP-1 obesity drug expected to drive growth.
See More
Jim Cramer's Trust Increases Stake in Cardinal Health
- Increased Stake: Jim Cramer's Charitable Trust purchased 25 shares of Cardinal Health at approximately $210, raising its total holdings to 475 shares and increasing its portfolio weighting from 2.5% to 2.6%, reflecting confidence in the company.
- Market Reaction: Cardinal Health's stock has pulled back about 9% since the onset of the conflict with Iran; however, the company is expected to see earnings per share grow approximately 25% in the current fiscal year, indicating strong profitability amid market volatility.
- Product Growth: Sales of GLP-1 medications have provided a significant tailwind to Cardinal's Pharmaceutical and Specialty Solutions business, contributing 6 percentage points to revenue growth in the most recent quarter, further solidifying its market position.
- Board Changes: The sudden retirement of Chairman Gregory Kenny, replaced by current director Patricia Hemingway Hall, may unsettle investors; however, the company clarified that this decision was not related to operational disagreements and maintains confidence in its future financial outlook.
See More
Cardinal Health to Release Q3 FY2026 Financial Results on April 30
- Earnings Release Schedule: Cardinal Health is set to release its third-quarter financial results for fiscal year 2026 on April 30, prior to the opening of trading on the New York Stock Exchange, ensuring timely access to critical information for investors.
- Webcast Discussion: The company will host a webcast discussion of the financial results starting at 8:30 a.m. Eastern, allowing investors to participate by visiting Cardinal Health's Investor Relations page without requiring an access code, thereby enhancing information transparency.
- Availability of Materials: Presentation slides and a replay of the webcast will be available on the Investor Relations page for 12 months, facilitating easy access for investors to review the information at their convenience and strengthening communication between the company and its investors.
- Company Overview: Cardinal Health operates as a distributor of pharmaceuticals and specialty products, a supplier of home-health and direct-to-patient services, and is committed to driving continuous improvement and innovative solutions that enhance people's lives through a customer-centric focus.
See More
Cardinal Health Appoints New Board Chair
- Board Leadership Change: Cardinal Health has appointed Patricia A. Hemingway Hall as Chair of the Board, succeeding the retiring Gregory B. Kenny, who has served since 2007 and as Chairman since 2018, during which he supported the company through significant transformations in strategic portfolio evolution and operational improvements.
- Experienced Leadership: Hemingway Hall has been on the Cardinal Health Board since 2013 and served as Chair of the Governance and Sustainability Committee for nearly seven years, bringing extensive healthcare leadership experience and deep institutional knowledge that will aid in executing the company's strategic priorities.
- Positive Financial Outlook: The company is set to release its third-quarter fiscal 2026 earnings on April 30, maintaining confidence in its fiscal 2026 outlook, which indicates stability and growth potential in the current market environment.
- Commitment to Continuous Improvement: Cardinal Health emphasizes a customer-centric approach, striving for operational efficiency through innovative solutions that enhance lives, showcasing its leadership position in the distribution and services of healthcare products.
See More
Cardinal Health Expands Ac-225 Production Capacity Significantly
- Production Capacity Boost: Cardinal Health has added a high-capacity production line at its Center for Theranostics Advancement in Indianapolis, significantly increasing the supply of cGMP-compliant Ac-225 to meet the growing demand for cancer therapies.
- Clinical Trial Support: To date, Cardinal Health's Ac-225 has supported over 15 clinical trials worldwide, reflecting the company's extensive engagement in advancing targeted alpha therapies and enhancing its position in pharmaceutical innovation.
- Market Demand Response: Since announcing routine global production at scale at the end of 2024, Cardinal Health has quadrupled its weekly output, with expectations to continue increasing production capacity in 2026 to meet the rapidly growing demand for targeted alpha therapies.
- Supply Chain Assurance: According to VP Shane Thrasher, expanding Ac-225 production capacity is a critical advancement for the industry and patients, ensuring reliable access to targeted alpha therapies and preparing for larger commercial volumes in the future.
See More
Market Volatility and Amazon's Acquisition Talks
- Market Volatility: Stocks experienced significant declines at the open on Thursday due to President Trump's hawkish remarks on the Iran war, which raised concerns and caused oil prices to surge; however, news of Iran working with Oman on a shipping protocol eased oil price pressures, allowing the S&P 500 to briefly trade higher, reflecting the market's high uncertainty.
- Amazon Acquisition Talks: Amazon is in negotiations to acquire satellite company Globalstar to advance its internet-from-space service, Leo, having launched about 200 low Earth orbit satellites despite competition from SpaceX's Starlink, which has over 10,000 satellites; this move is expected to enhance rural internet access and make Prime membership more attractive.
- Microsoft's AI Investment Lag: A profile on Microsoft CFO Amy Mood highlighted the company's conservative approach to AI spending, which has led to a competitive disadvantage, with the stock down 23% year-to-date; nevertheless, analysts remain optimistic about management's ability to address these challenges, maintaining a $600 price target.
- Rapid Stock Review: Stocks mentioned in Thursday's rapid-fire segment included Brinker, Texas Roadhouse, and Constellation Brands, indicating a focus on diversified investment strategies while emphasizing Jim Cramer's long-term holding approach in specific stocks within his charitable trust.
See More
CNBC Investing Club March Meeting Overview
- Energy Stocks Surge: Following the outbreak of war in Iran, energy stocks, particularly fertilizer manufacturers, have shown strong performance, indicating robust market demand that could drive profitability for related companies.
- AWS Growth Acceleration: Amazon's cloud unit AWS is no longer lagging behind Microsoft Azure, thanks to its partnership with Anthropic, with expectations for next quarter's margins to exceed market forecasts, boosting investor confidence.
- Cybersecurity Challenges: CrowdStrike has been affected by turmoil in the software market, but the CEO highlighted the positive impact of AI on cyberattacks, indicating long-term growth potential in the security sector, despite high stock prices.
- Healthcare Sector Risks: Eli Lilly faces pricing pressure from competitor Novo Nordisk, but the company is prepared to counter this by increasing volume, with the upcoming launch of its GLP-1 obesity drug expected to drive growth.
See More
Jim Cramer's Trust Increases Stake in Cardinal Health
- Increased Stake: Jim Cramer's Charitable Trust purchased 25 shares of Cardinal Health at approximately $210, raising its total holdings to 475 shares and increasing its portfolio weighting from 2.5% to 2.6%, reflecting confidence in the company.
- Market Reaction: Cardinal Health's stock has pulled back about 9% since the onset of the conflict with Iran; however, the company is expected to see earnings per share grow approximately 25% in the current fiscal year, indicating strong profitability amid market volatility.
- Product Growth: Sales of GLP-1 medications have provided a significant tailwind to Cardinal's Pharmaceutical and Specialty Solutions business, contributing 6 percentage points to revenue growth in the most recent quarter, further solidifying its market position.
- Board Changes: The sudden retirement of Chairman Gregory Kenny, replaced by current director Patricia Hemingway Hall, may unsettle investors; however, the company clarified that this decision was not related to operational disagreements and maintains confidence in its future financial outlook.
See More
Cardinal Health to Release Q3 FY2026 Financial Results on April 30
- Earnings Release Schedule: Cardinal Health is set to release its third-quarter financial results for fiscal year 2026 on April 30, prior to the opening of trading on the New York Stock Exchange, ensuring timely access to critical information for investors.
- Webcast Discussion: The company will host a webcast discussion of the financial results starting at 8:30 a.m. Eastern, allowing investors to participate by visiting Cardinal Health's Investor Relations page without requiring an access code, thereby enhancing information transparency.
- Availability of Materials: Presentation slides and a replay of the webcast will be available on the Investor Relations page for 12 months, facilitating easy access for investors to review the information at their convenience and strengthening communication between the company and its investors.
- Company Overview: Cardinal Health operates as a distributor of pharmaceuticals and specialty products, a supplier of home-health and direct-to-patient services, and is committed to driving continuous improvement and innovative solutions that enhance people's lives through a customer-centric focus.
See More
Cardinal Health Appoints New Board Chair
- Board Leadership Change: Cardinal Health has appointed Patricia A. Hemingway Hall as Chair of the Board, succeeding the retiring Gregory B. Kenny, who has served since 2007 and as Chairman since 2018, during which he supported the company through significant transformations in strategic portfolio evolution and operational improvements.
- Experienced Leadership: Hemingway Hall has been on the Cardinal Health Board since 2013 and served as Chair of the Governance and Sustainability Committee for nearly seven years, bringing extensive healthcare leadership experience and deep institutional knowledge that will aid in executing the company's strategic priorities.
- Positive Financial Outlook: The company is set to release its third-quarter fiscal 2026 earnings on April 30, maintaining confidence in its fiscal 2026 outlook, which indicates stability and growth potential in the current market environment.
- Commitment to Continuous Improvement: Cardinal Health emphasizes a customer-centric approach, striving for operational efficiency through innovative solutions that enhance lives, showcasing its leadership position in the distribution and services of healthcare products.
See More
